Interestingly, other researchers have proved that PGC1α expression is reduced because of endogenous accumulation of nitric oxide synthase inhibitor ADMA (asymmetric dimethylarginine) in both T1DM and T2DM rat models, thus suggesting it as a novel therapeutic target to prevent or treat DCM [88]. The gene discussed is PPARGC1A; the disease is familial dilated cardiomyopathy.